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The impact of whole-body hyperthermia interventions on mood and
depression – are we ready for recommendations for clinical application?
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ABSTRACT
Objective: To systematically summarize the findings from research studies examining the effects of
whole-body hyperthermia (WBH) interventions on mood and symptoms of depression.
Methods: Systematic literature search of online and offline databases (e.g., Pubmed, Web of
Knowledge, Cochrane, academic libraries). Risk of bias assessment and secondary analysis of
effect sizes.
Study selection: Clinical studies with a pre/post-intervention design and outcome measures for mood
and depression as accepted in the S-3 guidelines (Association of Scientific Medical Societies
in Germany).
Data extraction: Study characteristics and outcomes (means and standard deviations) from partici-
pants receiving at least one WBH intervention.
Results: A total of 7 studies and 148 subjects with a mean age of 46 years (36–56 years) were identi-
fied. Three out of seven studies utilized hot baths and 4/7 infrared heating. Study duration ranged
from 1 to 6weeks with one or multiple interventions and an average treatment time of 66.37min
(42.55–140). Risk of bias analysis revealed small sample biases and lack of control groups in 3/7 stud-
ies. About 21 study end-points were extracted with 19 resulting in effects sizes (Cohen’s d) of 0.8 or
greater. Target temperatures between 38 C and 39 C and slower increase in core body temperature
during the intervention resulted in larger treatment effects.
Conclusion: WBH is a promising alternative treatment for depression with low risk for adverse reac-
tions and side effects but still lacking sufficient evidence for general recommendations for clinical
practice. However, as all other interventions have failed, the studies to date can provide a framework
for clinical application.
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Background
Depression has become a serious population health issues
over the last decade with a significant medical, social and
economic burden. In the United States for example, 10.3%
of physician office visits indicated depression on the med-
ical records in 2014 with more than 40,000 people commit-
ting suicide [1]. According to the WHO, depressive disorders
will surpass coronary artery disease as leading causes of
debilitating illnesses by 2030 [2]. New and effective strat-
egies to address this continuously rising health issue are
needed. The S-3 guidelines from the Association of
Scientific Medical Societies in Germany (AWMF) [3] recom-
mend pharmacological and behavioral interventions for
mild to moderate depression and electroconvulsive therapy
(ECT) as the standard treatment for more severe and
chronic symptomology. About 20–30% of patients receiving
common, pharmacological treatments, do not respond to
the intervention or develop side effects [4,5]. Furthermore,
a treatment resistant depression has been associated with
significant alterations of cognitive functions and even sui-
cidal attempts [5,6]. This might reflect a need for effective
alternative treatments or interventions to complement com-
mon clinical practice. Historically and prior to pharmaco-
logical discoveries, depressive symptoms were commonly
treated with hyperthermia interventions. In fact, evidence
for the use of hyperthermia dates back as far as the times
of Galen of Pergamon (129–198 C.E.) who reportedly treated
melancholia successfully by bathing his patients in hot tubs
and massaging their skin [7]. Over the last years, whole-
body hyperthermia (WBH) interventions have received
renewed attention and several studies have examined its
effects on mental health and the potential clinical applica-
tion. This includes case reports, open-label studies and also
controlled and blinded trials. In 2016, we published the
results of a randomized, double blind and sham-condition
controlled study and provided the first scientific evidence
for the anti-depressant effect of a single WBH session in a
population diagnosed with depression. The published find-
ings resulted in significant discussion in the scientific
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communities, mostly due to the small sample size and the
relevance for clinical practice [8–10]. While this study was
the first to study the effects of whole-body heating on
depression in a controlled environment, earlier data are
available from quasi-experimental and observational reports
as well as from another controlled study published in 2017.
The present work systematically summarizes the findings
from all studies to date and aims to provide a validation of
study findings, an assessment of its value as well as recom-
mendations for clinical practice and future research.
Methods
An electronic search of publications related to our objective,
whole-body heating and depression, has been conducted in
Pubmed, Web of Knowledge, clinicaltrials.gov and the
Cochrane library. The literature search included the years
1950–2018. English and German keywords were used, such
as whole-body hyperthermia, heat therapy, hot tube, mood,
depression, depressive disorder, depressive affect, mental sta-
tus, Ganzk€orperhyperthermie, €Uberw€armungsbad, GkHT, GHT,
Depression, depressiver Affekt and mentaler oder depressiver
Status. A manual search of the libraries of the University of
Freiburg (Germany) and the University of Graz (Austria) was
conducted supplementary to the electronic search. Reference
lists from relevant publications were scanned as well as
authors contacted to provide additional information. Only
studies with human subjects and in English or German lan-
guage were included.
Study selection
Selection of studies was conducted in four steps. First, we
reviewed all publications matching our search criteria, inde-
pendent of format, study and publication quality and evi-
dence levels. Second, we excluded duplicates, single case-
reports and qualitative studies since comparing the results to
quantitative studies would not be appropriate. In a third step,
we excluded previous reports if a study and its population
was expanded and published consecutively at a later time. In
this case we only included the most recent publication. Last,
we selected all studies that utilized outcome measures for
mood and depression that are accepted in the S-3 guidelines
from the AWMF, such as Hamilton Depression Rating Scale
(HAM-D), Patient Health Questionnaire (PHQ-D), Center for
Epidemiologic Studies Depression Scale (CES-D), Beck
Depression Inventory (BDI) or Allgemeine Depressionsskala
(ADS) (German version of the CES-D). Please see Figure 1 for a
Figure 1. PRISMA study flowchart.
574 K.-U. HANUSCH AND C. W. JANSSEN
PRISMA study flowchart. Overall, our literature search identi-
fied 13 studies [11–23] for further review. After evaluating all
studies with the aforementioned criteria, the seven studies
[14,15,18,19,21–23] outlined below were selected for further
analysis and data extraction.
Schaper [14] reported data from 20 patients (5 males, 15
females) receiving WBH interventions during an in-patient stay
to treat their moderate uni- or bipolar symptoms. The average
age of the study population was 41.95 (9.76) and included
patients free of antidepressant medications as well as patients
with previous or active pharmacological treatments protocols.
All patients received a weekly passive WBH session in a bath-
tub. All sessions started with water temperatures of 37 C and
were increased by 1 C every 10min. Core body temperature
was monitored throughout the entire session using sublingual
thermometers. Prior to the intervention all patients received a
subcutaneous injection of Primula/Onoprodon cp 1% (1ml).
The number of interventions received ranged from 4 to 13,
depending on the length of the in-patient stay. Sessions were
concluded once the sublingual temperature did not increase
any further following increases in water temperature. The
average session duration was 42.55min (12.32) followed by a
60-min resting period wrapped in warm blankets. Core body
temperature was measured sublingually and averaged at a
maximum of 38.4 C and an increase of 1.72 C throughout
the intervention. HAM-D interviews were conducted the day
before the intervention and following every WBH session.
Statistically significant reductions in depressive symptomology
were reported following the second session and during the
second week.
G€odl [15] published the results from open-label, quasi-
experimental observations on 10 patients (m/w¼ 4/6) with
an average age of 41.67 (10.27). Only patients with diag-
nosed depressive disorder following The Diagnostic and
Statistical Manual of Mental Disorders (DSM-V) criteria from
the American Psychiatric Association were included and
patients with manic episodes or psychotic symptoms
excluded. Eight patients were under active anti-depressive
medication regimens and two reportedly did not take any
psychopharmaceuticals. As part of a multimodal approach,
study participants received a WBH treatment in a hot tub,
starting at a water temperature of 37 C and increasing by
1 C every 10min. Treatments were conducted once every
week for 6–8weeks. On average the maximum core body
temperature (measured sublingual) was 39.3 C with an aver-
age increase of 2.3 C during an average bathing time of
46.7 (6.9) min. Following the hot bath, study participants
rested for 1 h covered with a blanket to keep the warm.
HAM-D interviews were conducted at the end of the multi-
modal treatment phase and 50% of study subjects (N¼ 5)
were below the cutoff for depression. The focus of this study
was on heart rate variability and baseline HAM-D values
were unfortunately not obtained.
H€uppe [19] studied the effects of a 45-min intervention in
a WBH device (IRATHEM 1000) on mood in 36 patients diag-
nosed with lipophilic toxicants in a randomized controlled set-
ting. The study population had an average age of 56.20 (6.20)
and all participants were randomized to receiving either a 45-
min session with a temperature increase of 1–1.5 C rectal
temperature (experimental group, 12 patients), a 45-min ses-
sion with a temperature increase of less than 0.3 C (control,
12 patients) or no intervention at all (12 patients). Sessions
were conducted three times per week over a timeframe of
5weeks. ADS scores (German equivalent to the CES-D) were
obtained at baseline, week 1 and week 5 following the last
intervention. Pre-intervention ADS scores ranged from 13.50
(6.88) in the control group, to 17.33 (9.78) in the experimental
group and 18.17 (7.94) in the no intervention group. Subjects
with scores of 23 and greater on the ADS scale are considered
‘depressed’ and it is to note that the baseline values in this
study were below this clinical cutoff. However, results revealed
a reduction in depressive symptomology in the experimental
group from 17.33 (9.78) at baseline to 12.58 (10.53) at week 1
and 13.50 (9.04) at week 5 of the study. The control group
did not show any changes at all.
Hanusch [18] observed 17 patients (m/w¼ 5/12, age 46.65
(12.62)) also in a quasi-experimental study and moderate to
severe uni- or bi-polar depression. Three out of fourteen
patients were also treated with selective serotonin reuptake
inhibitors (SSRI) at the time they received the WBH interven-
tion. All subjects received a single hyperthermia session with
IR-A light exposure in a Heckel HT-2000 device. The maximum
core body temperature as measured with a rectal thermometer
averaged at 38.4 C with an increase of 1.2 C during the inter-
vention. Treatment duration on average was 46.2min followed
by a 60-min resting phase in the machine but without any
Table 1. Overview of all studies included.
Year Journal/book Design N all/exp Control Include/out
Studies summary information
Lampert [11] 1967 Bruno-Wilkens Verlag Hannover Qualitative – No Out
B€uhring [12] 1984 Hippokrates Verlag Stuttgart Qualitative – No Out
Koltyn [13] 1992 Int J Hyperthermia Case report 7/7 No Out
Schaper [14] 1996 Universit€atsbibliothek Freiburg Cohort pro-post design 20/20 No Include
G€odl [15] 2000 Universit€atsbibliothek Graz Cohort pre-post design 10/10 No Include
H€uppe [19] 2009 Act Nerv Super Rediviva RCT 36/12 Yes Include
Janssen [20] 2011 NHK Qualitative – No Out
Hanusch [16] 2013 NHK Cohort pre-post design (same sample AJP) 12/12 No Out
Hanusch [17] 2013 NHK Cohort pre-post design (same sample AJP) 15/12 No Out
Hanusch [18] 2013 AJP Cohort pre-post design 17/17 No Include
Romeyke [21] 2014 Journal of Musculoskeletal Pain CCT 103/55 Yes Include
Janssen [22] 2016 JAMA RCT 35/17 Yes Include
Naumann [23] 2017 BMC RCT 36/17 Yes Include
NHK: Die Naturheilkunde; AJP: American Journal of Psychiatry; BMC: Complementary and Alternative Medicine; RCT: randomized controlled study; CCT: controlled
clinical study.
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further exposure to infrared lighting or any other heating devi-
ces. The treatment end-point was defined with a particular pat-
tern in the increase in skin temperature rather than core body
temperature. During the sessions, study participants were
accompanied by clinical staff seated close to their head and
providing cold washcloths on the forehead frequently.
Hanusch found that the 14 patients who were currently free of
psychopharmaceutic drugs experienced statistically significant
reductions in depressive symptoms as measured with the ADS-
L (German version of the CES-D) and during the first week and
sixth week following the single session. Interestingly, the three
patients who were under current SSRI treatment protocols did
not experience any changes in depressive symptomology.
Romeyke [21] studied the effects of whole-body heating
in 103 patients (m/w¼ 2/102, average age 55.2 (10.0)) with
fibromyalgia and also diagnosed with severe depression
based on criteria from the American Psychiatric Association
(DSM-V) and the International Statistical Classification of
Disease and Related Health Problems. As part of this quasi-
experimental observational study, patients were asked to
complete a Patient Health Questionnaire (PHQ-D) with a
focus on mental well-being and depression. Study partici-
pants received multiple WBH sessions in a Heckel HT-2000
device with Infrared-A lighting for the duration of 50min
and a target temperature of 38.5 C. Following the interven-
tion, subjects rested for 60min while being covered with
blankets. Core body temperature was measured using a rec-
tal thermometer. When comparing the results to a control
group that did not receive hyperthermia interventions, they
did not find statistically significant differences between the
groups (p¼ 0.055).
Janssen [22] used a randomized, double-blind and sham-
condition controlled study design in 34 patients with depres-
sion as assessed with HAM-D interviews and multiple inter-
viewers. Seventeen study participants received an active
WBH treatment and 17 a sham intervention in a Heckel HT-
3000 device with water-filtered infrared-A heating. The aver-
age age of the 17 study participants who received the active
intervention was 36.71 (15.20) with a female/male ratio of
12/5. Heating was applied until the rectal temperature
reached 38.5 C. Following the heating session, all subjects
remained in the enclosed machine to rest for another 60min
without exposure to infrared light or any further heating.
Two separate teams were trained to maintain a double-blind
setting. Subjects were also accompanied by trained staff
seated next to the study participant’s head. On average the
maximum core body temperature was 38.85 C with an
increase of 1.91 C in the active treatment group and
37.69 C in participants receiving a sham treatment.
Treatment time was 47min on average (21–80min) followed
by a resting phase of 60min. HAM-D values were obtained
at baseline, 1, 2, 4 and 6 weeks after the one hyperthermia
session. Throughout the study period, statistically significant
improvements in mental condition, and reductions in
depressive symptomology respectively, measured with HAM-
D assessments occurred in the group receiving the active
treatment when compared to the group receiving the
sham session.Ta
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Naumann [23] is the most recent WBH study and exam-
ined the effects of a hot tub intervention in 17 patients with
depression. The study population was 47 years of age on
average (11.9) and the ratio males/females was 3/14. Results
were compared to a non-blinded control group of 19 sub-
jects who received a sham treatment of green LED light
exposure (10,000 Lux for 30min). All 17 subjects received 2
weekly hyperthermia interventions in the hot tub over the
course of 4weeks. Study participants were either lying or sit-
ting in a small pool-sized tub that was heated to 40.2 C (0.3)
for an average of 22.6min (3.5). Participants received the
intervention either individually or in a group setting.
Following the intervention, subjects rested for 33.2min (6.3)
while wrapped in warm blankets. Core body temperature
was measured using ear thermometers and temperature
increased from 36.6 C to 39.1 C (average increase of
2.43 C) followed by a decrease during the resting phase to
37.7 C on average. HAM-D values were obtained at baseline,
at 2 weeks and at 6 weeks. In the intervention group, effect
sizes of 0.84 and 0.86 were reported for the week 2 and
week 6 assessments, respectively. Statistically significant dif-
ferences between the groups were reported for the week 2
measure but not at week 6.
In summary, three open label studies and four controlled
studies were identified and selected for data extraction and
subsequently included for further statistical analysis (Table 1).
Data extraction
Means, standard deviations and number of participants were
extracted from the intervention groups from all selected
studies. To compare effect sizes across all studies, we
calculated Cohen’s standardized mean change for the treat-
ment group (dT) using the below formula [24]:
dT ¼ XTpreXTpostpooled standard deviationð Þ :
Effect sizes > 0.80 were considered large, 0.50–0.80 mod-
erate and 0.20–0.50 small, following Cohen’s recommenda-
tions. Additionally, 95% confidence intervals were calculated
with the below formula :
CI ¼ x61:96  r
n
Furthermore, study characteristics were extracted to
inform an analysis of biases following the Cochrane libraries
guidelines for randomized controlled trials and the recom-
mendations for the analysis of non-controlled studies [25].
Studies were either deemed as having low risk (þþ), poten-
tially low risk (þ), potentially high risk (-), high risk (- -) or
unclear risk (/). Summary scores were created for each study
analysis and described as percentages, with 20% as small
risk, 50% moderate risk and >50% high risk of study bias
(Tables 2 and 3).
Since only four studies reported having a control group,
we decided that the format of a common meta-analysis with
forest plot visualization would be inappropriate and decided
on a summary and comparison of the pre/post results from
the intervention groups only (Table 4). In addition to extract-
ing pre/post findings we analyzed the outcomes in associ-
ation with their potential risk for bias at all study end-points
and further conducted additional group comparisons based
on temperature, treatment times and frequency of interven-
tions. To visualize results we decided to utilize a GapMap
with bubbles due to the diversity of the data. GapMaps are a
Table 3. Risk of bias analysis for non-controlled studies.
Sum
risk of
bias (%)
Selection
bias
Was a
prospective
study
planning
applied?
Selection
bias
Were
inclusion
criteria
defined
beforehand?
Performance
bias
Was a
standardized
intervention
defined
beforehand?
Detection
bias
Were study
end-points
defined
beforehand?
Reporting bias
Was all
required
information
from all
patients
included or
information
suppressed?
Reporting
bias
Patient
information
was
transparently
reported and
not selectively?
Reporting
bias
Was a
complete
report of the
intervention
provided?
Reporting
bias
Was a
complete
report of all
results
provided?
Counts of the bias components
Schaper [14] 25% þ þ þ þ þ þ - - / þ þ þ þ þ þ
H€uppe [19] 13% þ þ þ þ - - þ þ þ þ þ þ þ þ þ þ
G€odl [15] 50% þ þ þ þ þ þ þ þ / - - - - - -
Romeyke [21] 17% þ þ þ þ þ - - þ þ þ þ þ þ þ þ
Hanusch [18] 29% - - - - þ þ þ þ þ þ þ þ þ þ þ
Janssen [22] 0% þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Naumann [23] 0% þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Table 4. Pre-post treatment effect sizes (Cohen’s d) with 95% confidence intervals, effect sizes >0.80 were considered large, 0.50–0.80 moderate and
0.20–0.50 small.
Week-1 Week-2 Week-3 Week-4 Week-5 Week-6
Standardized mean change for the intervention group
Schaper [14] 0.61 [0.03–1.24] 1.26 [0.58–1.94] 1.30 [0.62–1.98] 1.62 [0.84–2.34] 1.69 [0.83–2.34] 1.71 [0.90–2.43]
G€odl [15] 0.38 [0.80–1.54] 1.20 [0.09–1.73] 1.70 [0.25–2.16] 1.41 [0.10–1.97] 1.85 [0.33–2.26]
H€uppe [19] 0.47 [034–1.28] 0.41 [041–1.22]
Hanusch [18] 1.00 [0.29–1.72] 1.85 [0.80–2.67]
Romeyke [21] 1.28 [0.87–1.69]
Janssen [22] 1.15 [0.41–1.89] 1.38 [0.60–2.15] 1.59 [0.79–2.39] 1.61 [0.82–2.41]
Naumann [23] 0.84 [0.12–1.52] 0.86 [0.13–1.53]
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common method in epidemiological research where data are
often very heterogeneous.
Results
Seven studies on the effects of WBH on depression have
been identified and included in this analysis. Four studies
were controlled clinical trials. Overall, we were able to review
data from 148 (10–55) patients with an average age of 46
(36–56) who received one or more treatment sessions. The
majority of studies included patients currently taking psycho-
pharmaceutic medications. Hanusch [16–18] controlled for
antidepressant medication use in his analysis and Janssen
[22] excluded patients who were actively treated with pre-
scription drugs for depressive symptomology. Three studies
provided whole-body heating in a hot bath (one in a hot tub
and two in a hyperthermia bath), two utilized infrared-A
heating chambers (Heckel HT-2000) and two water-filtered
infrared-A heating chambers (one Heckel HT-3000 and one
IRATHERM). In five studies, participants received multiple
WBH sessions and in two studies only a single treatment was
given. The average session duration was 66.37min
(42.55–140.00). Core body temperature was measured with
various methods and four studies utilized rectal thermome-
ters, two studies measured temperature sublingual and one
study used an ear thermometer. Increases in measured tem-
perature ranged from 1.0 C to 2.43 C during the sessions.
No reliable average of core body temperature could be cal-
culated due to the various methods used to measure tem-
perature. Temperature measured sublingually seems to vary
significantly and temperature measured in participants ears
seems to be generally higher when compared to rectal
measures of temperature (Figure 3(D)). Study participants
were followed for a maximum of 6weeks and at minimum
for 1week. Two studies (G€odl and Naumann) had variable
treatment duration, two studies (Schaper and Romeyke) had
variable frequency of treatments and two studies (Schaper
and G€odl) had variable duration for the observation of
patients. Some studies had variable study end-points since
they observed patients during an in-patient stay and partici-
pation concluded with the end of the hospital stay. Six out
of seven studies found statistically significant reductions in
depressive symptomology somewhere between 1 and
6weeks post-intervention. Romeyke [21] did not report sig-
nificant findings when measuring depressive symptomology
using the PHQ-D assessment. Overall 21 study end-points
were provided from the studies with significant anti-depres-
sant effects reported for 19; only 2 end-points (H€uppe) did
not reach statistical significance. All studies were analyzed
for existing biases and grouped for their risk level. As
expected, open-label and non-controlled studies showed
increased risk for bias when compared to controlled clinical
studies. Three out of seven studies were grouped as high
risk for bias, two with a moderate risk and two as low risk
for bias (see Figure 2). After calculating effect sizes, 17 study
end-points revealed Cohen’s d values of 0.8 or higher and 4
study end-points had Cohen’s d effect sizes of less than 0.8
(Figure 4). A positive trend was observed over the course of
6weeks with increasing effect sizes (see GapMap visualiza-
tion). Eighteen out of 21 study end-points showed a progres-
sive increase in effects sizes, 2 out of 21 increased constantly
and 1/21 appears to decrease in effect size. Sample sizes
Figure 2. Relationship between risk of bias (%) and effect sizes from all studies; the bubble size¼ sample size (n) of studies experimental groups.
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ranged from 4 to 55 and therefore provided reduced power
and a small sample biases in select studies. Effect sizes were
independent of sample size however when comparing stud-
ies with large sample sizes (Romeyke) with smaller ones
(Schaper, Hanusch, G€odl and Janssen). Also, effect sizes seem
to be independent of total number of WBH sessions and fre-
quency as no differences can be reported between a single
session (Janssen and Hanusch) and multiple sessions
(Schaper, G€odl and Romeyke) (Figure 3(C)). Antidepressant
effects further occurred in both participants currently treated
with psychopharmarceutical drugs and without. Only one
study [16–18] controlled for use of antidepressant medica-
tion. The standard mean difference was calculated for the
four controlled trials (N¼ 99 in the intervention group and
N¼ 85 in the control group) using RevMan 5.3 and resulted in
0.59 [0.97, 0.21] with an effect size of z¼ 3.05 (p¼ 0.002)
for the first observations, suggesting that the active treatment
was more effective in patients with depressive symptomology.
Adverse events
Five out of seven studies reported adverse reactions during
or following a hyperthermia session. Those events were
either documented in medical records (Naumann, Schaper
and Hanusch) or collected with standardized assessment
such as the no observed adverse effect level and the patient
rated inventory of side effects (H€uppe and Janssen). Adverse
reactions during the sessions included restlessness, agitation,
tachycardia, emotional reactions such as anger, sadness or
feelings of incompetence and were reportedly of minor
nature. Following the hyperthermia intervention reactions
such as headaches, insomnia, vertigo, nausea, numbness in
extremities, ringing in ears and reduced interest in sexual
activities occurred also reportedly of short or very short dur-
ation and complete reversion. Both studies utilizing standar-
dized assessments did not find differences in adverse
reactions in comparison to the control group.
Limitations
The heterogeneous selection of studies, primarily in the
study end-points, intervention type, study population and
focus of the research study as well as measures applied is a
limitation to this project. Due to the lack of control groups
in 3/7 studies and missing information on responding and
non-responding study participants, calculating an appropriate
risk ratio and necessary number to treat was not possible.
Another limitation is the lack of separation between medi-
cated and non-medicated study participants. The work
Figure 3. (A) Relationship between core body temperature during the intervention (y-axis) and effect sizes (x-axis) in Celsius as grouped by measuring method
(orange¼ rectal temperature, green¼ sublingual temperature, red¼ ear temperature). (B) Relationship between the ratio of highest core body temperature and time
to reach the temperature (y-axis) and effect size (x-axis), grouped by intervention type (orange¼ infrared heating with IRATHERM device or Heckel device, green-
¼ intervention in a bath tub, red¼ hot tub). (C) Relationship between study end-point (y-axis) and effect size (x-axis) grouped by intervention frequency (green¼ sin-
gle session, red¼multiple sessions). (D) Relationship between the different methods of measuring core body temperature (x-axis) and core body temperature (y-axis).
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conducted by Hanusch and Nauman provides some prelimin-
ary evidence however.
Conclusion
Using a somewhat unconventional and innovative but scien-
tifically sound approach, we were able to combine and com-
pare the findings from a diverse set of seven studies
examining the effects of WBH on depression and mental
health. Our analysis revealed large effects sizes in 6/7 studies,
independent of sample size, total number and frequency of
treatment sessions as well as study quality. The data
reported by H€uppe [19] were the only to result in a small
effect size (Figure 4). This might be due to their study popu-
lation failing to reach the clinical cutoff for depression at
baseline on the ADS scale and it is questionable if the study
participants were suffering from depression and rather had
dysthymic disorders which are defined as episodic mood
changes over 2 or more years but lacking the overall number
of symptoms required for the diagnosis of clinical depression
[3]. According to the ADS scale, patients scoring between 16
and 23 are considered dysthymic. Three out of seven studies
were assessed as having small sample biases and lack of con-
trol groups. Small sample sizes are not uncommon in clinical
research and results can still be impactful for clinical guide-
lines. The German guidelines for the treatment of depression
for example include ECT as a treatment with high evidence
(level A). Assuming that larger scale studies using ECT have
been conducted, the guidelines use two systematic reviews
that summarized studies with small sample sizes. The evi-
dence at hand suggests that WBH is starting to become a
promising alternative treatment for depression. The results
from the seven studies to date can be used to guide its clin-
ical application and inform future research. It seems that a
slow increase in ambient temperature and a target core
body temperature of 38 C–39 C provides the largest effects
(Figure 3(B)). Interestingly, this might be a potential explan-
ation for sauna studies failing to provide similar results since
the ambient temperature in a sauna is set at the beginning
of the intervention. Future research should focus on examin-
ing the underlying biological and psychological mechanisms
of action and also the broader clinical applicability in for
example non-responders to pharmaceutical interventions or
as a complementary treatment to achieve cumulative effects.
For example, one mechanism through which WBH treat-
ments might improve mood is by activating temperature-
sensitive ion channels in the skin. Those have been shown to
signal directly to brainstem serotonergic neurons when acti-
vated during warmer temperatures [26]. We would also rec-
ommend future research studies to include study end-points
at week 1 to capture acute effects, during 6–12weeks to be
comparable to other interventions where this is a common
follow-up duration and further re-assess participants after
6months to study whether WBH can result in, or contribute
to, a complete remission of symptoms. For clinical applica-
tion a single WBH intervention with a target core body tem-
perature of 38.5± 0.5 C, measured rectally, appears to be a
valid recommendation, especially if achieved with a slow
increase in ambient temperature and followed by a resting
period of 60min. If symptoms relapse we would recommend
an additional intervention. Based on the findings summarized
above and the evidence to date we are convinced that WBH
Figure 4. Effect sizes at study end-points (weeks); the bubble size¼ sample size (n) of studies experimental groups.
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has the potential to become a promising alternative treatment
for depression but there is not sufficient evidence yet to rec-
ommend it for general application and to provide guidelines
for clinical practice. Further controlled and larger trials and
meta-analytic work is necessary. However, if physicians decide
to offer WBH as a last treatment option for patients if all other
interventions have failed, we recommend to apply a mild to
moderate treatment with core body temperatures of
38.5 C–40.5 C since this range has been proven most effect-
ive based on the evidence summarized in this paper.
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